Jerzy Z. Błoński

Medical University of Lodz — Poland

Medicine · Health Sciences

23h-index1.6kcitations109works8.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Chronic Lymphocytic Leukemia Research(89), Lymphoma Diagnosis and Treatment(47), Acute Lymphoblastic Leukemia research(28), Immunodeficiency and Autoimmune Disorders(26), Advanced Breast Cancer Therapies(11)

Publications109 total

Increased abundance of <i>Firmicutes</i> and depletion of <i>Bacteroidota</i> predicts poor outcome in chronic lymphocytic leukemia
Oncology Letters·2024· 8 citedOpen Access
PB1915: THE MULTI-FACETED ROLE OF ORAL AND GUT MICROBIOME IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA
HemaSphere·2023Open Access
Diagnostic and therapeutic recommendations of the Polish Society of Haematologists and Transfusiologists and Polish Adult Leukemia Group-CLL for chronic lymphocytic leukemia in 2021
Hematology in Clinical Practice·2021· 2 citedOpen Access
Diagnostic and therapeutic recommendations of the Polish Society of Haematologists and Transfusiologists and Polish Adult Leukemia Group-CLL for chronic lymphocytic leukemia in 2021
Acta Haematologica Polonica·2021· 2 citedOpen Access
A 5-year follow-up to evaluate the efficacy and safety of ofatumumab added to fludarabine and cyclophosphamide in patients with relapsed chronic lymphocytic leukemia: final analysis of the COMPLEMENT 2 trial
Leukemia & lymphoma/Leukemia and lymphoma·2020· 4 cited
Dose and drug changes in chronic lymphocytic leukemia cell response in�vitro: A comparison of standard therapy regimens with two novel cyclin‑dependent kinase inhibitors
Molecular Medicine Reports·2019· 4 citedOpen Access
Long-Term Evaluation of Efficacy and Safety of Ofatumumab Added to Fludarabine &amp; Cyclophosphamide in Subjects with Relapsed Chronic Lymphocytic Leukemia: Final Analysis of Complement 2 Trial
Blood·2018
Bendamustine alone or with rituximab modifies expression of apoptosis-regulating genes and proteins of CLL cells, depending on IGVH mutational status
Leukemia & lymphoma/Leukemia and lymphoma·2018
Rituximab, cladribine, and cyclophosphamide (RCC) induction with rituximab maintenance in chronic lymphocytic leukemia: PALG ‐ CLL4 (<scp>ML</scp>21283) trial
European Journal Of Haematology·2018· 9 citedOpen Access
Personalized therapy tests for the monitoring of chronic lymphocytic leukemia development
Oncology Letters·2017· 7 citedOpen Access
Randomized phase 3 study of lenalidomide versus chlorambucil as first-line therapy for older patients with chronic lymphocytic leukemia (the ORIGIN trial)
Leukemia·2017· 28 citedOpen Access
Prognostic value of thymidine kinase activity in patients with chronic lymphocytic leukemia.
PubMed·2016· 8 cited
Health-related quality of life and patient-reported outcomes of ofatumumab plus fludarabine and cyclophosphamide versus fludarabine and cyclophosphamide in the COMPLEMENT 2 trial of patients with relapsed CLL
Leukemia & lymphoma/Leukemia and lymphoma·2016· 11 cited
Ofatumumab plus fludarabine and cyclophosphamide in relapsed chronic lymphocytic leukemia: results from the COMPLEMENT 2 trial
Leukemia & lymphoma/Leukemia and lymphoma·2016· 57 cited
In vitro antileukemic activity of novel adenosine derivatives bearing boron cluster modification
Bioorganic & Medicinal Chemistry·2016· 20 cited
Rekomendacje diagnostyczne i terapeutyczne dla przewlekłej białaczki limfocytowej w 2016 r – Raport Grupy Roboczej PTHiT i PALG-CLL
Acta Haematologica Polonica·2016· 4 cited
Antibody therapy alone and in combination with targeted drugs in chronic lymphocytic leukemia
Seminars in Oncology·2016· 25 cited
Health-Related Quality of Life and Patient-Reported Outcomes in Patients Receiving Ofatumumab in Combination with Fludarabine and Cyclophosphamide (FC) Versus FC Alone in the Complement 2 Trial
Blood·2015· 5 cited
POTENTIAL GENETIC AGENT BFL1 FOR TARGETED THERAPY IN CHRONIC LYMPHOCYTIC LEUKEMIA
2015· 1 cited
Badania in vitro nad wpływem bendamustyny zastosowanej pojedynczo lub w skojarzeniu z rytuksymabem na komórki przewlekłej białaczki limfocytowej z uwzględnieniem stanu mutacyjnego IGVH
Acta Haematologica Polonica·2015
page 1 of 6Next →

Frequent Co-authors

Tadeusz Robak(49), Joanna Góra‐Tybor(15), Marek Kasznicki(13), Anna Dmoszyńska(10), Zofia M. Kiliańska(10), L Konopka(9), Aleksander B. Skotnicki(7), B. Ceglarek(7), Jadwiga Dwilewicz‐Trojaczek(7), Krzysztof Warzocha(7), Ewa Wawrzyniak(7), Andrzej Hellmann(6), Krzysztof Lewandowski(6), Janusz Kłoczko(6), Jacek Bartkowiak(6), Piotr Smolewski(6), Małgorzata Rogalińska(6), W. Nowak(5), Barbara Zdziarska(5), Krzysztof Jamroziak(5)